



HAL
open science

Intracellular lipids: an independent cause of liver injury and chronic kidney disease in non-alcoholic fatty liver disease-like context

Laure Monteillet, Monika Gjorgjieva, Marine Silva, Vincent Verzieux, Hervé Guillou, Gilles Mithieux, Fabienne Rajas

► To cite this version:

Laure Monteillet, Monika Gjorgjieva, Marine Silva, Vincent Verzieux, Hervé Guillou, et al.. Intracellular lipids: an independent cause of liver injury and chronic kidney disease in non-alcoholic fatty liver disease-like context. G2L2, Oct 2018, Genève, Switzerland. <inserm-02388687>

HAL Id: inserm-02388687

<https://inserm.hal.science/inserm-02388687v1>

Submitted on 2 Dec 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization

Intracellular lipids: an independent cause of liver injury and chronic kidney disease in non-alcoholic fatty liver disease-like context

Laure Monteillet¹, Monika Gjorgjieva¹, Marine Silva¹, Vincent Verzieux¹, Hervé Guillou²
Gilles Mithieux¹ and Fabienne Rajas¹

¹Nutrition, Diabetes and the Brain. Inserm1213, UCBL

²Inra - Toxalim, Toulouse University

Introduction: Ectopic lipid accumulation in the liver and kidneys is a hallmark of metabolic diseases, such as obesity and diabetes, leading to non-alcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD). Interestingly, ectopic lipid accumulation in both the liver and kidneys is also an important feature of a rare metabolic disease named Glycogen Storage Disease type Ia (GSDIa). GSDIa is caused by glucose-6 phosphatase catalytic subunit (G6PC) deficiency, entailing hypoglycaemia during short fasts. Moreover, G6Pase deficiency leads to glucose-6 phosphate accumulation in the liver and kidneys, leading to glycogen and lipid accumulation. With time, this results in the development of the same hepatic and renal long-term complications as obesity and diabetes, meaning NAFLD and CKD. Finally, in the obesity/diabetes field recent data have highlighted a strong correlation between NAFLD and CKD incidences. In this study, we first investigated whether and how a diet enriched in lipids could accelerate liver or kidney injuries in **two** mouse model of GSDIa with a specific deletion of *G6pc* in the liver or kidneys (L.G6pc^{-/-} and K.G6pc^{-/-} respectively). In parallel, using the same mouse models, we examined whether a drug activating intracellular lipid catabolism could prevent or delay NAFLD and CKD, respectively. Finally, a part of this study also allowed us to document whether NAFLD can influence the development of CKD or not.

Method: L.G6pc^{-/-} and K.G6pc^{-/-} mice were fed either a high fat high sucrose (HF/HS) or a standard (STD) diet for 9 months. A group of mice was fed a STD diet for 6 months and then with a fenofibrate-enriched diet for 3 additional months. After 9 months, lipid and glycogen metabolism were characterized, and NAFLD and CKD damages were evaluated.

Results: HF/HS diet exacerbated hepatic and renal lipid accumulation in L.G6pc^{-/-} and K.G6pc^{-/-} mice respectively. In L.G6pc^{-/-} mice, this resulted in an **increase** in liver injuries, characterized by higher levels of plasmatic transaminase, and increased hepatic tumor incidence. In K.G6pc^{-/-} mice, HF/HS diet accelerated the nephropathy, illustrated by an increase of urinary albumin and lipocalin 2 levels, and advanced fibrosis. In both cases the worsening of NAFLD injuries and CKD was independent of glycogen content. Furthermore, fenofibrate, *via* the activation of lipid oxidation, significantly decreased the hepatic or renal lipid accumulations and prevented liver or kidney damages in L.G6pc^{-/-} and K.G6pc^{-/-} mice. Finally, we show that L.G6pc^{-/-} and K.G6pc^{-/-} mice developed NAFLD and CKD independently.

Conclusion: This study highlights the crucial role that lipids play in the independent development of both NAFLD and CKD and demonstrates the importance of lipid-lowering treatments in various metabolic diseases featured by lipid load, from the “rare” GSDIa to the “epidemic” morbid obesity or type 2 diabetes.